Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Merck MRK announced positive topline data from two pivotal phase III studies evaluating the investigational, once-daily, oral ...

US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...

Moderna 's ( MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock ...

The U.S. healthcare system saw a significant 7.5% spending increase in 2023, reaching $4.9 trillion, driven largely by ...

The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.

Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

(RTTNews) - Merck & Co Inc. (MRK), Thursday reported topline results from two pivotal Phase 3 trials evaluating the company's drug candidate islatravir in combination with its approved HIV drug ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...